10x Genomics, Inc. TXG Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s unrealized losses on investments (before tax)?
- 10x Genomics, Inc. (TXG) reported unrealized losses on investments (before tax) of $10K in Q1 2026.
- How has 10x Genomics, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
- 10x Genomics, Inc.'s unrealized losses on investments (before tax) increased by 400.0% year-over-year, from $2K to $10K.
- What is the long-term trend for 10x Genomics, Inc.'s unrealized losses on investments (before tax)?
- Over 3 years (2022 to 2025), 10x Genomics, Inc.'s unrealized losses on investments (before tax) has grown at a -100.0% compound annual growth rate (CAGR), from $4.12M to $0.